瑞舒伐他汀对血管性痴呆患者认知功能障碍的疗效观察

目的探讨瑞舒伐他汀对改善血管性痴呆患者认知功能损害的疗效。方法将98例血管性痴呆患者随机分为瑞舒伐他汀钙片组（观察组）50例和常规治疗组（对照组）48例。两组患者均给予常规治疗（抗血小板聚集、改善脑循环、应用脑保护剂），对合并高血压、糖尿病患者控制血压和血糖水平。观察组在常规治疗的基础上，给予瑞舒伐他汀钙片1日10mg，每晚餐后口服。两组均治疗24周。治疗前、治疗后12周和24周时采用简易智能状态量表（MMSE）和日常生活能力量表（ADL）评价临床疗效。结果观察组治疗后MMSE评分与对照组治疗后比较，差异有统计学意义（P〈0．05）；观察组治疗后ADL评分与对照组治疗后比较，差异有统计学意艾（P〈0．05）。两组均未出现重大的不良反应，观察组仅出现轻度胃肠道反应、轻度肝功能异常及一过性头晕，无需特殊处理，动态观察后自行缓解；对照组出现轻度胃肠道反应及轻度头晕。结论瑞舒伐他汀钙片可能在改善血管性痴呆患者的认知功能，提高其生活质量存治疗作用。

Observation of the Effects of Rosuvastain on Cognitive Function Improve-ment of Patients with Vascular Dementia

OBJECTIVE To explore the effects of rosuvastain on cognitive function improvement of patients with vascular dementia. METHODS 98 patients with vascular dementia were divided into rosuvastain group（ observation group） of 20 cases and conventional treatment group （control group） of 48 cases. All patients received conventional therapy （such as antiplatelet aggregation, improve cerebral circulation, brain protective agent）, control blood pressure and blood sugar in patients with hypertension and DM. On the basis of routine treatment the control group received with rosuvastain 10mg · d-l, take the drug each night after the meal oral. Both groups were treated for 24weeks. Patients were assessed the clinical effects by mini-mental state examination （ MMSE）, activity of daily living scale （ADL） before and after the 12 week and 24 week treatment. RESULTS The MMSE scores of observation group and control group after treatment, has significant differences（ P 〈 0.05 ） ;The ADL scores of observation group and control group after treatment, there were significant differences （ P 〈 0.05 ） ; No major adverse reactions were found in both groups. Patients of observation group had slight gastric discomfort, mild liver dysfunction and transient dizzy,and no spec：al treatment was needed, after dynamical observation can relieve itself; Patients of control group had slight gastric discomfort and mild dizzy. CONCLUSION Rosuvastain may have effect in improving the cogni- tive function of patients with vascular dementia and enhance the quality of Life.